NCT06661850 Examination of Nociscan Impact on Low Back Pain Surgical Outcomes
| NCT ID | NCT06661850 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Aclarion |
| Condition | Low Back Pain |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-06-11 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2025-06-11 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is looking into how useful NOCISCAN is. NOCISCAN is a software as a Service (SaaS) tool that uses Magnetic Resonance (MR) spectroscopy. Nociscan leverages MRS to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. The randomized controlled trial will compare the blinded and unblinded cohorts and their corresponding surgical outcomes with the Nocigram reports, generated prior to treatment, for each patient.
Eligibility Criteria
Inclusion Criteria: 1. Subject is a skeletally mature male or female (non-pregnant) aged 18 to 70 years (inclusive); 2. Subject intends to undergo instrumented surgical treatment in the lumbar spinal disc for their lower back pain, independent of this research protocol; 3. Subject is to be treated with FDA-cleared or FDA-approved devices independent of this research protocol; 4. Subject has a preoperative Oswestry Disability Questionnaire score ≥35 out of 100 points (35/100); 5. Subject has a VAS back pain score of ≥40mm; 6. Subject has failed at least ≥ 6 months of non-operative treatment (for example: physical therapy, bed rest, anti-inflammatory or analgesic medications, chiropractic care, acupuncture, massage therapy or home-directed lumbar exercise programs) OR requires urgent surgical treatment per the investigator; 7. Subject has signed the IRB approved Informed Consent Form; and 8. Subject is psychosocially, mentally and physically able and willing to fully comply with this protocol including adhering to follow-up schedule and requirements and filling out forms. Exclusion Criteria: 1. Subject has had prior lumbar back surgery or intradiscal treatments at any lumbar level (Note: diagnostic provocative or anesthetic discography are not excluded; micro-discectomy, decompression, or laminectomy patients greater than 6 months postop are not excluded); 2. Subject has a lumbar spine diagnosis, based on radiographic evidence, of clinically relevant lumbar vertebral abnormalities (except Modic end-plate changes, which are not excluded), including: * Grade 3 Spondylolisthesis (Grade 1 or Grade 2 is allowed) * Pars fracture, at the involved level * Spondylolysis * Lumbar scoliosis with a Cobb angle of greater than 20° * Evidence of prior fracture or trauma to the L1, L2, L3, L4, or L5 levels in either compression or burst * Lumbar kyphosis 3. Subject is contraindicated for a standard lumbar MRI exam 4. Women who are currently pregnant (or believe they may be at risk of being or becoming pregnant), or are breast feeding, during the study period when scans will be performed 5. Subject has a chronic disease (other than degenerative disc disease), chronic pain (other than low back pain), or psychological dysfunction, which may, in the opinion of the Principal Investigator, compromise a subject's ability to comply with study procedures, and/or may confound data
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06661850 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Low Back Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06661850 currently recruiting?
Yes, NCT06661850 is actively recruiting participants. Contact the research team at rbond@aclarion.com for enrollment information.
Where is the NCT06661850 trial being conducted?
This trial is being conducted at Phoenix, United States, Beverly Hills, United States, La Jolla, United States, Los Angeles, United States and 6 additional locations.
Who is sponsoring the NCT06661850 clinical trial?
NCT06661850 is sponsored by Aclarion. The trial plans to enroll 300 participants.